StockData

China SXT Pharmaceuticals, Inc. (SXTC) stock

SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30
$2.86−0.13 (-4.35%)

Close on Nov 17, 2026Market cap $2.74MP/E –Yield –

China SXT Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was -$7.12M. The highest annual figure on record is $1.77M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$7.12M–
FY2025Mar 31, 2025-$2.68M–
FY2024Mar 31, 2024-$2.52M–
FY2023Mar 31, 2023-$5.61M–
FY2022Mar 31, 2022-$5.19M–
FY2021Mar 31, 2021-$2.20M–
FY2020Mar 31, 2020-$1.34M-175.8%
FY2019Mar 31, 2019$1.77M+8.4%
FY2018Mar 31, 2018$1.63M+1.9%
FY2017Mar 31, 2017$1.60M–

More China SXT Pharmaceuticals figures

See a number that looks wrong?